Kyverna Therapeutics
KYTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +151.3% in FY2025
Warner Biddle is the CEO of Kyverna Therapeutics and was paid $1.8M in FY2025 (Dec), down 88%.
Pay$100 in the stock at the end of FY24 → $251
Executives3
See all- 1Naji Gehchan, M.D.Chief Medical and Development OfficerFY2025
- 2Warner BiddleChief Executive OfficerFY2025
- 3Marc Grasso, M.D.Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allKyverna Therapeutics paid its 3 named executives $5.6M in total in FY2025 (Dec). CEO Warner Biddle was paid $1.8M of that.
| Name | |||
|---|---|---|---|
| Naji Gehchan, M.D.Chief Medical and Development Officer | Not disclosed | Not disclosed | |
| Warner BiddleChief Executive Officer | Not disclosed | ||
| Marc Grasso, M.D.Chief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Kyverna Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Beth Seidenberg, M.D.Director · 7 yr on the boardIndependentScience and Technology—Paid as an executive
- Mert AktarDirector · 1 yr on the boardIndependentAudit, Science and Technology—Paid as an executive
- Andrew Miller, Ph.D.Director · -1 yr on the boardIndependentAudit, Science and Technology—Paid as an executive
- Sravan EmanyDirector · -1 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 13, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 14, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
| Annual report | 10-K | Mar 26, 2024 | FY2023 |
